<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901143</url>
  </required_header>
  <id_info>
    <org_study_id>Sheba-21-8159-at-ctil</org_study_id>
    <nct_id>NCT04901143</nct_id>
  </id_info>
  <brief_title>Meal Handling of Advanced Closed Loop Insulin Delivery.</brief_title>
  <official_title>Meal Handling of Advanced Closed Loop Insulin Delivery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will Compare meal related glycemic indices following 2 types of meal announcement:&#xD;
&#xD;
        1. Conventional assessment of carb content plus carb equivalence of proteins and fat&#xD;
&#xD;
        2. Algorithm device optimal universal meal announce equivalent&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in range</measure>
    <time_frame>300 minutes</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Advanced hybrid closed loop system</intervention_name>
    <description>Phase 1: meals in open loop- 3 weeks Phase 2: closed loop conventional meal announcement- 3 weeks Phase 3: closed loop, pre define universal bolus- 3 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is 20 to 70 years of age at time of screening&#xD;
&#xD;
          2. Subject's weight is between 50 and 120 kg&#xD;
&#xD;
          3. A clinical diagnosis of Type 1 diabetes as determined by the Investigator for a&#xD;
             minimum of 36 months prior to enrollment&#xD;
&#xD;
          4. Subject has ongoing use of an insulin pump and rtCGM ≥ 6 months prior to screening&#xD;
&#xD;
          5. current use of 670G 4.0 pump&#xD;
&#xD;
          6. Subject has an A1C value ≤ 10.0% demonstrated at the time of enrollment.&#xD;
&#xD;
          7. Subject uses a rapid-acting analogue insulin in his/her pump&#xD;
&#xD;
          8. Patient is willing to undergo all study procedures&#xD;
&#xD;
          9. English proficiency&#xD;
&#xD;
         10. Minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8&#xD;
             units&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subject who has a positive serum pregnancy screening test, or who plans to&#xD;
             become pregnant during the course of the study&#xD;
&#xD;
          2. Subject has unresolved adverse skin condition, or unable to tolerate tape adhesive, in&#xD;
             the area of sensor placement or device replacement (e.g., psoriasis, rash,&#xD;
             Staphylococcus infection)&#xD;
&#xD;
          3. Subject has a history of hypoglycemic seizure or hypoglycemic coma within the past 12&#xD;
             months&#xD;
&#xD;
          4. Subjects currently taking adjunct therapy with SGLT2-inhibitors, Amylin.&#xD;
&#xD;
          5. Subject has a history of seizure disorder unrelated to diabetes within the past 12&#xD;
             months&#xD;
&#xD;
          6. Gastroparesis, uncontrolled thyroid disorder, Addison disease,. , Pituitary&#xD;
             insufficiency&#xD;
&#xD;
          7. Subject has a history of myocardial infarction, unstable angina, coronary artery&#xD;
             bypass surgery, coronary artery stenting, transient ischemic attack (TIA),&#xD;
             cerebrovascular accident (CVA), congestive heart failure, ventricular rhythm&#xD;
             disturbances, or thromboembolic disease within the past 6 months&#xD;
&#xD;
          8. Subject has a presence of a cardiac pacemaker or any other device that may be&#xD;
             sensitive to radio frequency telemetry&#xD;
&#xD;
          9. Subject has any condition, including screening lab values that in the opinion of the&#xD;
             Investigator may preclude him/her from participating in the study and completing study&#xD;
             related procedures&#xD;
&#xD;
         10. Subject is actively participating in other investigational study (drug or device)&#xD;
&#xD;
         11. Subjects who consume alcohol daily&#xD;
&#xD;
         12. Use of CGM (other than per protocol) throughout the duration of the study&#xD;
&#xD;
         13. Use of Hydroxyurea medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amir Tirosh, Prof.</last_name>
    <phone>+972526666777</phone>
    <email>Amir.tirosh@sheba.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maya Laron Hirsh</last_name>
    <phone>+972544706640</phone>
    <email>Maya.laron-hirsh@sheba.gov.il</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Amir Tirosh</investigator_full_name>
    <investigator_title>Prof. Amir Tirosh</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

